Boston Scientific Corp (BSX)vsStryker Corporation (SYK)
BSX
Boston Scientific Corp
$56.85
-1.53%
HEALTHCARE · Cap: $83.97B
SYK
Stryker Corporation
$290.88
+1.50%
HEALTHCARE · Cap: $112.88B
Smart Verdict
WallStSmart Research — data-driven comparison
Stryker Corporation generates 23% more annual revenue ($25.27B vs $20.61B). BSX leads profitability with a 17.3% profit margin vs 13.2%. BSX appears more attractively valued with a PEG of 0.68. BSX earns a higher WallStSmart Score of 71/100 (B).
BSX
Strong Buy71
out of 100
Grade: B
SYK
Buy57
out of 100
Grade: C
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-23.3%
Fair Value
$46.11
Current Price
$56.85
$10.74 premium
Margin of Safety
-9.7%
Fair Value
$265.08
Current Price
$290.88
$25.80 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Earnings expanding 100.0% YoY
Large-cap with strong market position
Growing faster than its price suggests
Strong operational efficiency at 20.6%
Generating 1.0B in free cash flow
Large-cap with strong market position
Areas to Watch
No major concerns identified
Premium valuation, high expectations priced in
2.6% revenue growth
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : BSX
The strongest argument for BSX centers on EPS Growth, Market Cap, PEG Ratio. Profitability is solid with margins at 17.3% and operating margin at 20.6%. Revenue growth of 11.6% demonstrates continued momentum.
Bull Case : SYK
The strongest argument for SYK centers on Market Cap. PEG of 1.40 suggests the stock is reasonably priced for its growth.
Bear Case : BSX
No major red flags identified for BSX, but monitor valuation.
Bear Case : SYK
The primary concerns for SYK are P/E Ratio, Revenue Growth, Piotroski F-Score.
Key Dynamics to Monitor
BSX profiles as a mature stock while SYK is a value play — different risk/reward profiles.
SYK carries more volatility with a beta of 0.93 — expect wider price swings.
BSX is growing revenue faster at 11.6% — sustainability is the question.
BSX generates stronger free cash flow (1.0B), providing more financial flexibility.
Bottom Line
BSX scores higher overall (71/100 vs 57/100), backed by strong 17.3% margins and 11.6% revenue growth. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Boston Scientific Corp
HEALTHCARE · MEDICAL DEVICES · USA
Boston Scientific Corporation, doing business as Boston Scientific, is a manufacturer of medical devices used in interventional medical specialties, including interventional radiology, interventional cardiology, peripheral interventions, neuromodulation, neurovascular intervention, electrophysiology, cardiac surgery, vascular surgery, endoscopy, oncology, urology and gynecology.
Stryker Corporation
HEALTHCARE · MEDICAL DEVICES · USA
Stryker Corporation is an American multinational medical technologies corporation based in Kalamazoo, Michigan. Stryker's products include implants used in joint replacement and trauma surgeries; surgical equipment and surgical navigation systems; endoscopic and communications systems; patient handling and emergency medical equipment; neurosurgical, neurovascular and spinal devices; as well as other medical device products used in a variety of medical specialties.
Visit Website →Compare with Other MEDICAL DEVICES Stocks
Want to dig deeper into these stocks?